Prosensa Strengthens its Management Team and Supervisory Board with Key
Preparing for anticipated launch of lead compound for DMD
Leiden, The Netherlands, June 30, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding
N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare
diseases with a high unmet medical need, today announced the appointment of
Willem W. van Weperen to the new position of chief commercial officer and the
addition of Dr. Annalisa Jenkins to its Supervisory Board.
With more than two decades of experience at Genzyme and GSK and his recent
leadership of Dutch to-BBB as CEO, Mr. van Weperen brings significant business
operational and commercial expertise to Prosensa in advance of an anticipated
launch of the company's first product for the treatment of Duchenne muscular
Hans Schikan, CEO of Prosensa said, "We expect Willem to play a critical role
at Prosensa as we move from a research and development stage company to a
commercial organization. His knowledge and experience will be invaluable as we
build the infrastructure to support the anticipated launch of our first
product for treating boys with DMD."
Prior to his role at to-BBB, Mr. van Weperen spent 15 years at Genzyme in a
number of senior management and commercial positions at both a national and
international level. He joined Genzyme in 1994 as medical affairs manager in
Europe. Subsequently, he worked as Area Manager Therapeutics for the Benelux,
responsible for sales and marketing of Genzyme's orphan disease products
following which he took on the role as European Marketing Director for the
Company's LSD/Thyrogen products. Since 2003, he assumed global responsibility
for marketing in the rare genetic disease business unit in Genzyme's worldwide
headquarters in Cambridge, MA. Most recently, he led Genzyme's Netherlands
organization in Naarden. At Genzyme, he oversaw and significantly contributed
to several global launches of products in the company's rare disease
"I'm thrilled to be joining Prosensa at such an exciting and pivotal time for
the company and look forward to applying my expertise in commercializing rare
disease drugs to potentially launching one of the first products to treat
DMD," said Mr. van Weperen.
Dr. Jenkins joins Prosensa's Supervisory Board with more than 25 years of
experience in the healthcare sector. In her most recent role as Head of Global
Research and Development and Executive Vice President at Merck Serono, which
she has held since October 2013, she was responsible for building global
development, research and medical capabilities, spanning research,
development, global regulatory and clinical development in addition to
medical affairs and patient access. She joined the company in 2011,
previously serving as Executive Vice President Global Development and Medical.
Prior to joining Merck Serono, Dr. Jenkins held various regional and global
roles with Bristol-Myers Squibb since 1997, most recently as Senior Vice
President, Global Medical Affairs.
"We are delighted to welcome Annalisa to Prosensa's Supervisory Board. Her
extensive experience in research and clinical development and medical affairs
for Merck Serono and Bristol Myers Squibb, which are amongst the top pharma
companies in the world, will bring valuable insights to us as we take the
company to the next level," said David Mott, Chairman of the Supervisory Board
Dr. Jenkins began her career as a Medical Officer with the British Royal Navy
after graduating in Medicine from St. Bartholomew's Hospital London and
training in Cardiovascular Medicine in the UK National Health Service.
"I am excited to join Prosensa at such a significant moment in the company's
history and look forward to working alongside a world-class team with
exceptional leadership in rare diseases," saidDr. Jenkins. "With such an
extensive research and development pipeline in DMD, I hope to integrate my
expertise in global R&D as Prosensa continues to advance its portfolio of
innovative exon-skipping technology."
The appointment of Dr. Annalisa Jenkins will be subject to shareholders'
approval at the next shareholders' meeting, scheduled for August 20, 2014.
Notes to editors
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the
discovery and development of RNA-modulating therapeutics for the treatment of
genetic disorders. Its primary focus is on rare neuromuscular and
neurodegenerative disorders with a large unmet medical need, including
Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington's
Prosensa's current portfolio includes six compounds for the treatment of DMD,
all of which have received orphan drug status in the United States and the
European Union. The compounds use an innovative technique called exon-skipping
to provide a personalized medicine approach to treat different populations of
DMD patients. www.prosensa.com
CONTACT: Celia Economides
Prosensa Holding N.V.
Sr Director IR & Corporate Communications
Prosensa Holding B.V. Logo
Press spacebar to pause and continue. Press esc to stop.